Cytokinetics Insider Sold Shares Worth $1,287,000, According to a Recent SEC Filing
Andrew Callos, Executive Vice President, Chief Commercial Officer, on July 01, 2026, sold 15,000 shares in Cytokinetics (CYTK) for $1,287,000. Following the Form 4 filing with the SEC, Callos has control over a total of 58,555 common shares of the company, with 58,555 shares held directly. SEC Filing
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.